| Autor: |
Armstrong AJ; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, 27710, USA. andrew.armstrong@duke.edu., Geva R; Division of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, affiliated to the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Chung HC; Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea., Lemech C; Scientia Clinical Research, Randwick, NSW, Australia., Miller WH Jr; Segal Cancer Center, McGill University, Jewish General Hospital, Montreal, QC, Canada., Hansen AR; Princess Margaret Cancer Centre, Toronto, ON, Canada., Lee JS; Seoul National University Bundang Hospital, Gyeonggi-Do, South Korea., Tsai F; Honor Health, Scottsdale, AZ, USA., Solomon BJ; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Kim TM; Seoul National University Hospital, Seoul, South Korea., Rolfo C; Center for Thoracic Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA., Giranda V; Merck & Co., Inc, Rahway, NJ, USA., Ren Y; Merck & Co., Inc, Rahway, NJ, USA., Liu F; Merck & Co., Inc, Rahway, NJ, USA., Kandala B; Merck & Co., Inc, Rahway, NJ, USA., Freshwater T; Merck & Co., Inc, Rahway, NJ, USA., Wang JS; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA. |
Full text from SpringerLink